missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human Activin R1B (ALK-4) Fc Chimera Recombinant Protein
Description
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type IB receptor, composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.
Specifications
Specifications
| Accession Number | P36896 |
| Concentration | 200 μg/mL |
| For Use With (Application) | Control, ELISA, Western Blot |
| Formulation | PBS with no preservative |
| Gene ID (Entrez) | 91 |
| Molecular Weight (g/mol) | 38.3 kD |
| Name | Human ACVR1B (aa 32-126) His Tag |
| Quantity | 25 μg |
| Source | CHO cells |
| Storage Requirements | -20°C |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?